Lexaptepid pegol: Phase IIa data

Data from 9 patients in the single-blind, crossover Part 1 of a 2-part, double-blind, placebo-controlled, U.K. Phase IIa trial showed that NOX-H94 was generally well tolerated and all adverse events o...